Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Cell Immunotherapy + Sintilimab + Chemotherapy in First-line Advanced NSCLC
NCT03987867Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous cytokine-induced killer cells and sintilimab in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
autologous cytokine-induced killer cellssintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03987867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987867.